

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 5 | 3 | — | — | 8 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 2 | 1 | — | — | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | — | — | 1 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | 1 | 1 | — | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 3 | — | — | — | 3 |
| Ulcer | D014456 | MPATH_579 | — | — | 3 | — | — | — | 3 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 3 | — | — | — | 3 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 2 | — | — | — | 2 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | 2 | — | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Drug common name | Obefazimod |
| INN | obefazimod |
| Description | Obefazimod is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Small molecule |
| Drug class | immunomodulators |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1 |
| PDB | — |
| CAS-ID | 1258453-75-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297344 |
| ChEBI ID | — |
| PubChem CID | 49846599 |
| DrugBank | DB14828 |
| UNII ID | 26RU378B9V (ChemIDplus, GSRS) |
